Who Paid My Doc
Brian Cooley
Gastroenterology Plano, TX Medical Doctor
NPI 1518926146 CMS profile 159690
1600 Coit Rd, Suite 401, Plano, TX 75075
General payments
$152,416
Research payments
$0
Ownership & investment interest
$12,841
Through program year 2022, Brian Cooley of Plano, TX is reported in the CMS Open Payments database as having received $152,416 across 177 general payments and $0 in research payments paid to them. They also declared ownership or investment interests valued at $12,841 across 4 holdings.
No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.
General payments for this record sit in the 97th percentile of Gastroenterology profiles with reported payments. Percentile describes the distribution, not the conduct.
By program year
8 rows| Year | Kind | Relative to this record's peak year | Amount | Records |
|---|---|---|---|---|
| 2022 | General | $14,004 | 13 | |
| 2021 | General | $26,561 | 26 | |
| 2020 | General | $7,065 | 9 | |
| 2019 | General | $104,787 | 129 | |
| 2024 | Ownership | $6,031 | 1 | |
| 2023 | Ownership | $6,031 | 1 | |
| 2022 | Ownership | $379 | 1 | |
| 2021 | Ownership | $401 | 1 |
Beside peers
- Brian Cooley
- Gastroenterology median
- Middle half of Gastroenterology
- National median
In program year 2025, general payments to Brian Cooley were reported at $0. Among 13,050 Gastroenterology profiles paid that year, the median was $639 and the middle half received between $167 and $1,700.
Show as a table
| Year | Brian Cooley | Gastroenterology median | Middle half | National median |
|---|---|---|---|---|
| 2019 | $104,787 | $417 | $126–$1,100 | $163 |
| 2020 | $7,065 | $224 | $74–$624 | $114 |
| 2021 | $26,561 | $352 | $106–$1,054 | $132 |
| 2022 | $14,004 | $448 | $129–$1,270 | $149 |
| 2023 | $0 | $533 | $150–$1,390 | $160 |
| 2024 | $0 | $605 | $160–$1,606 | $164 |
| 2025 | $0 | $639 | $167–$1,700 | $169 |
Breakdown
A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.
Prescribing to Medicare patients
Part D · data year 2024 · 3 drugsPart D claims
66
Drug cost
$1,073
Branded share of claims
0%
| Drug | Type | Relative to their largest | Claims | Drug cost |
|---|---|---|---|---|
| Famotidine | Generic | 19 | $398 | |
| Pantoprazole Sodium | Generic | 27 | $352 | |
| Omeprazole | Generic | 20 | $322 |
Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 104,182 Part D prescribers listed as Internal Medicine; they describe a distribution and say nothing about conduct.
Records
177 reportedEvery payment, record by record
Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.
Other Gastroenterology in Texas
Related records
Gastroenterology in Texas
Practitioners in the same specialty and state, ranked by reported value.
All Gastroenterology
Everyone recorded under this specialty, nationwide.
Doctors in Texas
Every practitioner in the state with a reported payment.
How to read this page
What each amount means, and what it does not mean.
What this means
U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.
An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.
Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.